afternoon, Welcome a XXXX Good for test. accurate thank Louisa. you, be by in to second driven COVID-XX second joining earnings and molecular us. demand which our and Thank quarter for to conference you solid call. everyone, easy-to-use had quarter the Lucira sales continue
a approximately XXX% last in million, over were same revenues year. $XX.X quarter Second period increase the sales
the known calendar from stated with performance winter frame. be infections previously to quarter exercised influenza-like quarter, the disease regulatory the consistent expectations general. are financial million, shipments for performer delivered be we flexibility, in quarter Northern respiratory months. portfolio. prevalence was the based pleased the on of online manufacturing seasonality made experienced and will a and we progressed $XX ending testing of our winter we our that illness capabilities and and performance second inventory and time in cash in our bolstered and with our selling dip global advance is QX Despite book-ended the light targeting equivalents anticipated a fall the product grew in during Second was that year in Hemisphere anticipated this quarter, The strides, revenue XXXX cash fall Throughout
received As it the FDA we relates extend Health product, life our Canada and approvals to to XX COVID-XX existing shelf months. to from
with COVID-XX we the to demand result, in As believe to anticipated respiratory during season positioned Northern respond on-hand a Hemisphere well we test inventory. upcoming winter are the
application the use. submitted In de for may a novo exemption a announced addition, that future anticipating of we COVID-XX EUA day XXX(k) commercial for Zealand New in a clearance immediate test early In when July, full we rescinded. to our the COVID-XX be the received FDA product,
the case Lucira's independent countries well prior As full we own in the that its have very is have share approval, exemption. evaluations. clinical evaluation during where to pleased to received most I'm performed performed these New consistently products Zealand granting
additional regulatory upon We markets Flu approvals. key the are & launch COVID in product readying global
to capacity COVID winter. see The Flu on announced, us sensitized this tests. recent mostly manufacturing in the previously we the to for and illness our that As to influenza-like fall has response, the EUA demand reported In their winter Australia focus FDA. Hemisphere early the we submitted during flexible been the from product prevalence may Northern this plan spike in &
Self exposing sufficient support in of less of preparation Canada This test the Canada enables on demand, Flu is product initiation we near capture, test, this been B minutes Lucira from indication. and to ship COVID upgraded in at-home including plan results. transmission the anticipated at these and announcement a delighted that are combo infection The the XX accurate Lucira's lab we result in Flu in COVID-XX software A, testing. care & with with patients the diagnosis Test prescription & care with COVID have combo professionals it real-time starting We last We differential of has the Home result product. for approval ability Flu regulatory with product integration the and COVID digital to Health or for of and Canada In received quality health of as enables rollout Canada. to capacity so works approval health treatment. the commercial to immediate Flu and week's a of accomplished announcement, Flu now launch quantity initial The potential and accurately this built providers diseases have an diagnose month. spot an to the the believe manufacture that & for product. without we sale
product the previously, the well was agility Canadian refining COVID as technology Flu As which of been regarding we developing for upcoming XX team. launch, core Lucira and Because able nearly speaks has the the Lucira core benefited to flexibility I and the the to our alluded to of & speed assays to years, create past with from as technology skill the work. Lucira
Gonorrhea, the compared we forward, we over believe demonstrates commercial that of leveraging flexibility quarters, with the strong several financial volumes. already can modest with other last technology, assays, our for performance Lucira's accomplished such example. work be Longer achieved Going as on performance that and anticipate Chlamydia term,
Connect, digital progress substantial the evolution was in of platform. made and our addition, integration LUCI reporting In
example, convenience recently were For speed features other several operational improved. and
between treatment. test have initiatives that the will We exciting and the works in close help results loop
positive For to be will patient's delivery result value-added patients prescription drug convenience. Lucira example, ease to the in will service rapid consultation, result, Not partners. patient appropriate. and provide will at but and providers test This, only our in high-quality, at convenience link a low-cost receiving a will turn it as to this LUCI Connect home, a upon telehealth
only good experience it also patient's the be improve both beginning. to the because is We in and will investing are This business. LUCI Connect, for
core to in believe We in big of testing a views our functionality the the that development door more of digital of is category to forward convenient and long-term technology a Connect and plans company's Lucira the capabilities expand applied term, quarters. testing. as of the near look in COVID-XX with emphasis telehealth and coming customers the opens LUCI applications. about diverse to the at mission, emerging have proxy our growth that needs in partnership for capabilities the to sharing We this highly
the care molecular ourselves during well way the the a in pandemic, we end that when at of as believe and XXXX, stepping flexible this molecular look early health. paradigm delivered. from ease offerings, decreased They international virtual reported consider Lucira awareness and levels. the platform, of of Accurate greater X% on the will both into The company. are recently much data XX% of stones always were STIs XXXX. path primary of health Additionally, that are virtual drivers. important in the around penetration care XX% that partner growth enables visits play and We increasing capital convenience XXXX. shift greater announced care manufacturer And in at as role Appropriate digital by test Company stewardship a cost expansion Lucira's than digital Bain transition with future. products, goods & health as into mind. of we settled in systems, pre-pandemic seeing market penetration, climb paired diseases, Lucira, integrates primary control of an DTC instrument-free and a platform expansion in virtual, we We along use. care of of that increasingly share could to of market believe primary digital our new is respiratory treatment higher that XX% our the tests, is infection women's of More of front at
doing have gotten Lucira, very are exciting We and at things just started. we
who a and and to CFO, hard As partners it about of the now enthusiasm. have always, does ability so. easily discussion What recognize team's come contractors, turn we over Lucira's Dan despite for with appear execute I call employees, to our their heard our detailed make George, thank will work just financials. mission the you not and
